ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.
AstraZeneca Pharma disclosed a ₹1.88 lakh penalty from the Registrar of Companies due to a delay in filing Form MR-2.
AstraZeneca Pharma India's Dr. Sandeep Arora resigned as Director, Medical Affairs, effective September 15, 2026. The company is seeking a suitable replacement for the position.
AstraZeneca Pharma India reported receiving an ESG rating of 64 from Crisil ESG Ratings. The assessment was independently prepared using publicly available information.
The Delhi High Court has stayed the NPPA's demand notice regarding Betaloc-50 overcharging allegations until February 2027, subject to a 15% deposit of the total demand amount.
AstraZeneca Pharma India has been assigned an ESG rating of 57 by Crisil ESG Ratings based on publicly available information.
AstraZeneca Pharma India Limited appointed Mr. Arun Krishna as a Non-Executive Director effective August 17, 2026. Additionally, Ms. Bhavana Agrawal transitioned to a Non-Executive Director role.
AstraZeneca reported 30% revenue growth to ₹682.8 Crore in Q1 FY2026-27, driven by strong performance across its core Oncology and Biopharmaceutical therapy areas.
AstraZeneca Pharma India held its 47th Annual General Meeting on August 10, 2026, where shareholders approved financial statements, dividend declaration, and key director and auditor appointments.
AstraZeneca Pharma India Ltd reported revenue from operations of ₹682.8 Cr (+29.7% YoY) and net profit of ₹37.9 Cr (-32.1% YoY) for Q1 FY27.
AstraZeneca Pharma received CDSCO permission to market 'Enhertu' for an additional breast cancer indication in India. This expands the drug's therapeutic usage under regulatory approval.